OPKO Health Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: OPKO Health Inc.
Former names: Exegenics Inc Cytoclonal Pharmaceutics Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Miami
Headquarters state / province: Florida
Headquarters country: United States
Fiscal year end: December
Ticker symbol: OPK
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000944809
EIN: 75-2402409

Board of directors

Follow this board

Alexis Borisy · Director Overboarded
Since 2023
Alice Lin-Tsing Yu · Director
Since 2023
Elias A. Zerhouni · Director · Vice Chairman and President
Since 2023
Gary J. Nabel · Director · Chief Innovation Officer
Since 2023
Jane Ph D. Hsiao · Director · Vice Chairman & CTO
Since 2023
John A. Paganelli · Director
Since 2023
Phillip Md Et Al Frost · Director · CEO & Chairman
Since 2023
Prem A. Lachman · Director
Since 2023
Richard C. Pfenniger Jr. · Director
Since 2023
Richard M. Krasno · Director
Since 2023
Roger Medel M.D. · Director
Since 2023
Steven D. Rubin · Director · Executive VP-Administration Overboarded
Since 2023
Subbarao Uppaluri V · Director
Since 2026

Chief executives

Phillip Md Et Al Frost · CEO & Chairman

Dates unknown

Director election results

Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

7 of this board's directors also sit on 15 other boards. 12 are in the same sector.

Shared director Other board Same sector

Cocrystal Pharma Inc. Same sector
via Phillip Md Et Al Frost, Richard C. Pfenniger Jr. and Steven D. Rubin
BioCardia Inc. Same sector
via Richard M. Krasno
Candel Therapeutics Inc. Same sector
via Gary J. Nabel
Danaher Corporation
via Elias A. Zerhouni
Eloxx Pharmaceuticals Inc. Same sector
via Steven D. Rubin
Entera Bio Ltd. Same sector
via Steven D. Rubin
Fluent Inc.
via Richard C. Pfenniger Jr.
GeneDx Holdings Corp. Same sector
via Richard C. Pfenniger Jr.
Niagen Bioscience Inc. Same sector
via Steven D. Rubin
Parabilis Medicines Inc. Same sector
via Alexis Borisy
Red Violet Inc.
via Steven D. Rubin
Relay Therapeutics Inc. Same sector
via Alexis Borisy
Revolution Medicines Inc. Same sector
via Alexis Borisy
SIGA Technologies Inc. Same sector
via Gary J. Nabel
Tango Therapeutics Inc. Same sector
via Alexis Borisy

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $2,995,366; 33 purchases by 2 insiders
Sold, last 12 months: $24,577; 2 sales by 1 insider

Date	Insider	Transaction	Shares	Price	Value
Nov 5, 2026	John A. Paganelli Director	Open-market sale	−4,426	$1.78	$7,878
Nov 5, 2026	John A. Paganelli Director	Open-market sale	−9,175	$1.82	$16,699
Jul 24, 2026	Adam Logal Officer (Sr. Vice President, CFO)	Shares withheld for tax	−53,266	$1.22	$64,985
Jul 24, 2026	Steven D. Rubin Director, Officer (Executive VP-Administration)	Shares withheld for tax	−53,266	$1.22	$64,985
Mar 20, 2026	John A. Paganelli Director	Open-market purchase	+10,000	$1.14	$11,400
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+102,371	$1.30	$133,082
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+3,894	$1.32	$5,140
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+89,375	$1.33	$118,869
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+191,490	$1.33	$254,682
Nov 21, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+192,870	$1.34	$258,446
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+119,129	$1.32	$157,250
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+47,105	$1.33	$62,650
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+211,948	$1.33	$281,891
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+161,818	$1.34	$216,836
Nov 20, 2025	Phillip Md Et Al Frost Director, Officer (CEO & Chairman), 10% owner	Open-market purchase	+24,579	$1.34	$32,936

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about OPKO Health Inc.

Who is the CEO of OPKO Health Inc.?

Phillip Md Et Al Frost is OPKO Health Inc.'s CEO & Chairman.

How many directors are on OPKO Health Inc.'s board?

OPKO Health Inc.'s board has 13 directors: Alexis Borisy, Alice Lin-Tsing Yu, Elias A. Zerhouni, Gary J. Nabel, Jane Ph D. Hsiao, John A. Paganelli, Phillip Md Et Al Frost, Prem A. Lachman, Richard C. Pfenniger Jr., Richard M. Krasno and 3 others.

Are OPKO Health Inc. insiders buying or selling shares?

Over the last 12 months, OPKO Health Inc. insiders bought $3.0 million of shares in 33 purchases and sold $24,577 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is OPKO Health Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="opko-health-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.